OCUL
OCULAR THERAPEUTIX, INC
Next earnings Aug 3, 2026 (after close) · consensus $-0.40 EPS, $13.5M rev
Last earnings -0.6% on 2026-05-05
$9.84
▲ +0.82%$9.84▲ +17.56%
over 1Y
L $6.88EODHDH $16.11
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W-1.3%
1M+15.2%
3M+30.3%
YTD-16.8%
1Y+17.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy
Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -18.5% YoY.
Revenue (FY2025) $52.0M · FY2025
OCULAR THERAPEUTIX, INC shows $52.0M in FY2025 revenue (-18.5% YoY), a -511.9% net margin, and -40.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$78.0M | -$78.7M | -$82.4M | -$172M | -$270M |
| Net income | -$6.55M | -$71.0M | -$80.7M | -$194M | -$266M |
| Diluted EPS | -$0.98 | -$0.97 | -$1.02 | -$1.22 | -$1.42 |
| Net margin | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.41B
EV / EBITDA—
EV / Sales27.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-12.4%
FCF yield-10.1%
Quality & risk
ROIC (est.)-32.6%
Free cash flow-$217M
Total debt—
Net cash$737M
Altman Z-Score6.40 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+36.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-102026-06-12open ↗4Period ending 2026-06-032026-06-05open ↗144Filing2026-06-03open ↗4Period ending 2026-05-262026-05-28open ↗
Frequently asked
- Is OCULAR THERAPEUTIX, INC (OCUL) a buy?
- OCUL currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -18.5% YoY.
- What is OCULAR THERAPEUTIX, INC's quality score?
- OCUL scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001393434, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 6:02:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.